Riad Mechlaoui

Biography

 The manufacture of injectable products requires specialised and sterile manufacturing facilities and techniques, and in some cases dedicated machinery, which must meet the strict quality standards imposed by regulatory authorities. Complying with these stringent regulatory requirements, as well as capital intensive manufacturing processes, demands significant continuous investment. At the same time, investment in training and development programmes is essential to ensure the highest levels of precision are implemented throughout the manufacturing process. These factors have created a market with high barriers to entry and, as a result, a limited number of competitors relative to other segments. Specialised technical capabilities, high running costs and the requirement for dedicated operational facilities have further restricted market entry. 

Research Interest

 From early on, the Injectables business has been an important driver of growth for the Group. As our business has grown, so has the diversity of our product portfolio and manufacturing capabilities. Through our Bedford acquisition, we now have a state-of-the-art R&D centre focused on introducing more differentiated products and an exciting pipeline, enhanced by our own business development and R&D efforts. This will enable us to access a broader range of attractive growth opportunities. As a manufacturer of hospital products used for critical care, we not only have to ensure that the highest quality standards are adhered to and implemented at all times, but to also prioritise patients’ and physicians’ needs. We have seen an increase in demand for a wider range of medicines as well as advanced, high-quality delivery systems. Both patients and doctors are now requiring better, faster access to treatments and technology, and we are focusing on expanding our portfolio and enhancing our technological capabilities to be able to meet this demand.